- Recruiting
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902
Updated: May 23, 2022
BMT CTN 1902
NCT05032820: Phase 2: MM CAR-T to Upgrade Response BMT CTN 1902

MM CAR-T to Upgrade Response BMT CTN 1902
This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patients with multiple myeloma (MM).
Sponsor
Marcelo Pasquini, MD
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Blood and Marrow Transplant Clinical Trials Network
National Cancer Institute (NCI)
National Marrow Donor Program
Celgene a wholly owned subsidiary of BMS
Information provided by (Responsible Party)
<